Loading clinical trials...
Loading clinical trials...
Pivotal Clinical Study to Establish the Safety and Effectiveness of the Use of BioTraceIO Lite for Assessment of Tissue Damage Following Liver Tissue Ablation Procedures
Conditions
Interventions
BioTraceIO Lite
Locations
6
United States
Mayo Clinic
Phoenix, Arizona, United States
Stanford Medicine
Stanford, California, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Mayo Clinic
Rochester, Minnesota, United States
University Hospitals Cleveland
Cleveland, Ohio, United States
Houston Methodist Hospital
Houston, Texas, United States
Start Date
September 24, 2021
Primary Completion Date
October 8, 2022
Completion Date
October 8, 2022
Last Updated
April 18, 2023
NCT06454578
NCT05870969
NCT05240950
NCT02221778
NCT05389527
NCT05908786
Lead Sponsor
Techsomed Medical Technologies LTD
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions